A Contemporary Role of Beta Blockers in Myocardial Infarction
Cardiology and Angiology: An International Journal,
Page 23-27
DOI:
10.9734/ca/2022/v11i430203
Abstract
Myocardial infarction (MI) is characterized by plaque formation in the inner layer of arteries which occurs due to insufficient or complete cessation of oxygen supply in the myocardium. The common symptoms of MI are crushing or squeezing chest pain which radiates to the arms, shoulders, neck, or jaw, nausea, anxiety, restlessness, fear, heartburn, shortness of breath, cold sweat, fatigue, and dizziness. The treatment of this medical condition includes antiplatelet and thrombolytic therapy, painkillers (morphine or meperidine), diuretics and digitalis glycosides drugs. Moreover, nitroglycerin and antihypertensive drugs such as Beta-blockers, ACE inhibitors, or Calcium channel blockers may also be administered to reduce the blood pressure and improve the oxygen supply in the heart. Among them, beta blocker therapy has several beneficial properties such as it reduces myocardial oxygen demand, preventing arrhythmias, and improves ventricular remodeling, etc. However, there is no study on the role of only beta blocker therapy in the survival of MI patent is found to date. Thus, the present study focused on the evidence-based validation of Beta blocker therapy in the treatment and survival of MI patients. The retrospective study was conducted on 51 MI patients under the observation of medical practitioners. 100% of patients with MI showed a good recovery as well as survival percentage with Beta blocker therapy. This study finally concluded that beta blocker therapy is a safe and effective treatment for MI patients with negligible life-threatening medical conditions. Furthermore, a large group study is suggested with a number of health-related parameters for a better understanding of beta blocker as a first line of treatment for MI patients.
Keywords:
- Acute coronary syndrome
- myocardial infarction
- symptoms
- beta blockers
- retrospective study
How to Cite
References
Elnoaas SMAA, El Sheikh RG, Elaal1 MAA, El Sheikh AA. The Correlations between Admission Heart Rate and Corrected QT Interval Prolongations with Coronary Artery Disease in Patients with Acute Coronary Syndrome. Cardiol Angiol: Int J. 2021;10(4):13-21.
Ojha N, Dhamoon AS. Myocardial infarction. InStatPearls [Internet] 2020. StatPearls Publishing.
Mechanic OJ, Gavin M, Grossman SA. Acute myocardial infarction.
Lu L, Liu M, Sun R, Zheng Y, Zhang P. Myocardial infarction: symptoms and treatments. Cell Biochemistry and Biophysics. 2015 Jul;72(3):865-7.
Gulati R, Behfar A, Narula J, Kanwar A, Lerman A, Cooper L, Singh M. Acute myocardial infarction in young individuals. InMayo Clinic Proceedings. 2020 Jan 1 (Vol. 95, No. 1, pp. 136-156). Elsevier.
Alkhouli M, Alqahtani F, Jneid H, Al Hajji M, Boubas W, Lerman A. Age-stratified sex-related differences in the incidence, management, and outcomes of acute myocardial infarction. InMayo Clinic Proceedings. 2021 Feb 1 (Vol. 96, No. 2, pp. 332-341). Elsevier.
Haig C, Carrick D, Carberry J, Mangion K, Maznyczka A, Wetherall K, McEntegart M, Petrie MC, Eteiba H, Lindsay M, Hood S. Current smoking and prognosis after acute ST-segment elevation myocardial infarction: new pathophysiological insights. Cardiovascular Imaging. 2019 Jun 1;12(6):993-1003.
RCPA. Myocardial infarction 2022; Accessed:https://www.rcpa.edu.au/Manuals/RCPA-Manual/Clinical-Problems/M/Myocardial-infarction#:~:text=Cardiac%20Troponin%20I%20or%20Troponin,for%20the%20diagnosis%20of%20MI.
Erhardt L, Herlitz J, Bossaert L, Halinen M, Keltai M, Koster R, Marcassa C, Quinn T, Van Weert H. Task force on the management of chest pain. European Heart J. 2002 Aug 1;23(15):1153-76.
Zhang K, Yang W, Zhang M, Sun Y, Zhang T, Liu J, Zhang J. Pretreatment with antiplatelet drugs improves the cardiac function after myocardial infarction without reperfusion in a mouse model. Cardiology Journal. 2021;28(1):118-28.
Chung J, Han JK, Kim YJ, Kim CJ, Ahn Y, Chan Cho M, Chae SC, Chae IH, Chae JK, Seong IW, Yang HM. Benefit of vasodilating β‐blockers in patients with acute myocardial infarction after percutaneous coronary intervention: Nationwide multicenter cohort study. J Am Heart Assoc. 2017 Oct 24;6(10):e007063.
Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Z J Med. 1981; 304(14):801-7.
-
Abstract View: 42 times
PDF Download: 18 times
